{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:17:34Z","timestamp":1788445054926,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroglobulin (Tg) measurement is key for differentiated thyroid cancer (DTC) follow-up, but anti-Tg antibodies (TgAbs) can interfere with Tg immunoassays and bias Tg interpretation. Current TgAb cutoffs are heterogeneous, and an assay-specific interference threshold is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 85 949 euthyroid health-screening records (Roche e801 platform) using segmented linear regression and 1000 bootstrap resamples to estimate a TgAb interference threshold. For external validation, 125 TgAb-positive post-thyroidectomy papillary thyroid carcinoma (PTC) patients were included, and receiver operating characteristic (ROC) analyses were performed. Two ROC analyses were performed: (a) low-TgAb patients without structural recurrence (Group A) vs patients with structural recurrence (Group C), and (b) Groups A + B (no structural recurrence, including persistently elevated TgAb) vs Group C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The population-derived TgAb interference threshold was 48.1 U\/mL (95% CI, 45.1\u201350.6). Above this level, Tg values shifted toward lower ranges with increased distributional asymmetry. In the PTC validation cohort, ROC-derived thresholds were 45.64 U\/mL (A vs C) and 50.14 U\/mL (A + B vs C), with areas under the curve (AUCs) of 1.00 and 0.8764, supporting internal stability and clinical concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>On the Roche cobas e801 platform, a TgAb level near 48 U\/mL provides a pragmatic interference threshold for Tg immunoassay interpretation. This threshold stratifies Tg interpretability and is concordant with ROC-derived cutoffs from clinically defined comparisons in a TgAb-positive PTC cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfag072","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:32:28Z","timestamp":1777116748000},"page":"1108-1121","source":"Crossref","is-referenced-by-count":0,"title":["A Large-Scale Study Identifies a TgAb Interference Threshold for Thyroglobulin Immunoassays Using Segmented Regression and Bootstrap Validation"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-6065","authenticated-orcid":false,"given":"Qianhui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"You","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heye","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026090309522327200_jfag072-B1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000341362","article-title":"Large discrepancy in the results of sensitive measurements of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma","volume":"1","author":"Nygaard","year":"2012","journal-title":"Eur Thyroid J"},{"key":"2026090309522327200_jfag072-B2","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/jc.2014-1203","article-title":"Serum thyroglobulin monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications","volume":"99","author":"Spencer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090309522327200_jfag072-B3","article-title":"Thyroglobulin assay interferences: clinical usefulness of mass spectrometry methods","volume":"7","author":"Barbesino","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026090309522327200_jfag072-B4","doi-asserted-by":"crossref","first-page":"E1074","DOI":"10.1210\/jc.2015-1967","article-title":"Thyroglobulin testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes","volume":"100","author":"Netzel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090309522327200_jfag072-B5","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0137","article-title":"Clinical irrelevance of lower titer thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma","volume":"11","author":"Dekker","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026090309522327200_jfag072-B6","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1210\/clinem\/dgae286","article-title":"Influence of thyroglobulin autoantibodies on thyroglobulin levels measured by different methodologies: immunometric assay, LC\u2013MS\/MS, and RIA","volume":"109","author":"Petrovic","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090309522327200_jfag072-B7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/thy.2016.0210","article-title":"Thyroglobulin liquid chromatography\u2013tandem mass spectrometry has low sensitivity for detecting structural disease in patients with antithyroglobulin antibodies","volume":"27","author":"Azmat","year":"2017","journal-title":"Thyroid"},{"key":"2026090309522327200_jfag072-B8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/jc.2010-2762","article-title":"Current thyroglobulin autoantibody assays often fail to detect interfering thyroglobulin autoantibodies that can result in the reporting of falsely low or undetectable serum thyroglobulin immunometric assay values in patients with differentiated thyroid cancer","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090309522327200_jfag072-B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2018.0195","article-title":"Clinical applicability of low levels of thyroglobulin autoantibodies as cutoff point for thyroglobulin autoantibody positivity","volume":"29","author":"Dekker","year":"2019","journal-title":"Thyroid"},{"key":"2026090309522327200_jfag072-B10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.774275","article-title":"Antithyroglobulin antibody variation during follow-up has prognostic value in preoperative antithyroglobulin antibody-positive differentiated thyroid cancer patients","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026090309522327200_jfag072-B11","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1515\/cclm-2017-0034","article-title":"Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up","volume":"55","author":"Katrangi","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2026090309522327200_jfag072-B12","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1093\/ejendo\/lvad109","article-title":"Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus","volume":"189","author":"Giovanella","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026090309522327200_jfag072-B13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ajcp\/aqw228","article-title":"Thyroglobulin antibody screening prior to mass spectrometry provides measurable cost savings and optimal laboratory utilization","volume":"147","author":"Powers","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2026090309522327200_jfag072-B14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2014-2725","article-title":"Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer","volume":"100","author":"Lupoli","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090309522327200_jfag072-B15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1089\/thy.2019.0368","article-title":"Antithyroglobulin antibody as a prognostic marker for differentiated thyroid cancer: a systematic review and meta-analysis","volume":"30","author":"Lee","year":"2020","journal-title":"Thyroid"},{"key":"2026090309522327200_jfag072-B16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1089\/thy.2017.0052","article-title":"Effect of thyroglobulin autoantibodies on the metabolic clearance of serum thyroglobulin","volume":"28","author":"Latrofa","year":"2018","journal-title":"Thyroid"},{"key":"2026090309522327200_jfag072-B17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.11613\/BM.2012.038","article-title":"Serum thyroglobulin antibody levels within or near to the reference range may interfere with thyroglobulin measurement","volume":"22","author":"Locsei","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2026090309522327200_jfag072-B18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1515\/CCLM.2011.155","article-title":"Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays","volume":"49","author":"Giovanella","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"2026090309522327200_jfag072-B19","doi-asserted-by":"crossref","first-page":"110995","DOI":"10.1016\/j.clinbiochem.2025.110995","article-title":"Defining a clinically relevant thyroglobulin antibody interference threshold for high-sensitivity thyroglobulin immunoassays: a single institution case study","volume":"139","author":"Patel","year":"2025","journal-title":"Clin Biochem"},{"key":"2026090309522327200_jfag072-B20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1515\/cclm-2021-1046","article-title":"Thyroglobulin and thyroglobulin antibodies: assay-dependent management consequences in patients with differentiated thyroid carcinoma","volume":"60","author":"van Kinschot","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"2026090309522327200_jfag072-B21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s12020-020-02526-8","article-title":"The role of a new polyclonal competitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer with structural disease but low serum thyroglobulin levels by immunometric and LC\u2013MS\/MS methods","volume":"72","author":"Guastapaglia","year":"2020","journal-title":"Endocrine"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/5\/1108\/68537791\/jfag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/5\/1108\/68537791\/jfag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:52:32Z","timestamp":1788443552000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/11\/5\/1108\/8709320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfag072","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,17]]}}}